Summary BackgroundTo evaluate the efficacy and safety of intravitreal bevacizumab injections in patients with pigment epithelial detachments (PEDs) secondary to age-related macular degeneration (AMD). Material and methodsIn a retrospective interventional case series, 62 eyes of 61 patients were treated with 1.5 mg bevacizumab intravitreally. Baseline and follow-up visits included best-corrected visual acuity and optical coherence tomography (OCT) examinations. Follow-up visits were performed 1, 3, and 6 months after initial treatment. Morphological effects on PED were quantified by repetitively measuring the highest elevation on two perpendicular OCT cross-sections. If height of PED was increased by 50 microns, or intraretinal fluid appeared or increased, or visual acuity decreased more than 5 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart, patients were reinjected. ResultsOn OCT, PED decreased from 346 ± 148 µm at baseline to 241 ± 159 µm (p < 0.001) at 1 month, 227 ± 193 µm (p < 0.001) at 3 months, and 166 ± 170 µm (p < 0.001) at 6 months. Mean best corrected visual acuity (BCVA) increased from 49 ± 18 letters at baseline to 52 ± 21 letters (p = 0.062) at 1 month. However, 3 and 6 months after initial injection mean BCVA returned to baseline levels (3 months: 49 ± 19 letters, p = 0.518; 6 months: 49 ± 20 letters, p = 0.053). On average, patients received 2.5 injections during the observation period of 6 months. Except for one retinal pigment epithelial (RPE) tear no other ocular or systemic adverse events were noticed. Ocular inflammation was not found in any of the investigated patients. ConclusionsThe presented data demonstrate a therapeutic effect of intravitreal bevacizumab in patients with specific classes of pigment epithelial detachments secondary to AMD.
epithelial          1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Epithelium            

bevacizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Bevacizumab           

AMD                           0.9999977642426057^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Advanced_Micro_Devices

bevacizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Bevacizumab           

µm                            0.9999996324409715^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Micrometre            

AMD                           0.9999977642426057^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Advanced_Micro_Devices

epithelial                    1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Epithelium            

visual acuity                 1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Visual_acuity         

optical coherence tomography (OCT)1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Optical_coherence_tomography

microns                       0.9999999999986358^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Micrometre            

intravitreal                  1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Intravitreal_administration

epithelial                    1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Epithelium            

visual acuity                 1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Visual_acuity         

µm                            0.9999996324409715^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Micrometre            

bevacizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Bevacizumab           

visual acuity                 1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Visual_acuity         

RPE                           1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Retinal_pigment_epithelium

intravitreal                  1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Intravitreal_administration

pigment                       0.9980272313982892^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Pigment               

pigment                       0.9980272313982892^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Pigment               

µm                            0.9999996324409715^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Micrometre            

retinal                       1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Retina                

age-related macular degeneration1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Macular_degeneration  

inflammation                  0.9999891849475288^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Inflammation          

µm                            0.9999996324409715^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Micrometre            

pigment                       0.9980272313982892^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Pigment               

